Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC

Trial design and data reporting

The primary objective of this open-label, first-in-human, phase 1, three-arm umbrella trial (ClinicalTrials.gov: NCT02316457) was to separately assess the feasibility, safety, and tolerability profile of two…